FT-536

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameFT-536
Drug Alias NameFT-536
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-MICAAnti-MICB
TargetsMHC class I polypeptide-related sequence AMHC class I polypeptide-related sequence B
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsGenital Neoplasms, Female +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics IncMasonic Cancer Center, University Of Minnesota
Inactive CompaniesN/A
Active IndicationsSolid tumoursFallopian Tube NeoplasmsGenital Neoplasms, Female +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A